ReviewClinical & experimental metastasis2015
Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy.
Review in Clinical & experimental metastasis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Association of tumor markers CA 15-3, CEA, and CA 125 with [Frontiers in oncology · 2025Article
- Oncological and functional outcomes of pathological fractures of lower extremities in patients with malignant bone tumors.Molecular and clinical oncology · 2024Article
- Treatment algorithm for metastatic malignancies in the lower extremities.Molecular and clinical oncology · 2024Article
- Value of CT-based radiomics in evaluating the response of bone metastases to systemic drug therapy in breast cancer patients.Thoracic cancer · 2024Article
- How to Target Spinal Metastasis in Experimental Research: An Overview of Currently Used Experimental Mouse Models and Future Prospects.International journal of molecular sciences · 2021Review
- Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells.Frontiers in cell and developmental biology · 2020Article
- A rare case of cancer-to-cancer metastasis: breast cancer to renal cell cancer : Case report and review of literature.Wiener medizinische Wochenschrift (1946) · 2019Review
- Pain prevalence and treatment in patients with metastatic bone disease.Oncology letters · 2019Article
- CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2019Article
- Co-delivery of dihydroartemisinin and docetaxel in pH-sensitive nanoparticles for treating metastatic breast cancerRSC advances · 2018Article
- Label-free Raman spectroscopy provides early determination and precise localization of breast cancer-colonized bone alterations.Chemical science · 2018Article
- Targeting the Metastatic Bone Microenvironment by MicroRNAs.Frontiers in endocrinology · 2018Review
- Pain and quality of life in breast cancer patients.Clinics (Sao Paulo, Brazil) · 2017Article
- Article
- Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis.Oncogene · 2017Review
- Management of Bone Metastases From Breast Cancer in Upper and Lower Body at the Same Time: A Case Report.World journal of oncology · 2016Article
- Age-related differences in persistence with bisphosphonates in women with metastatic breast cancer.Journal of bone oncology · 2016Article
- Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.Human gene therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most common female cancer worldwide with approximately 10 % of new cases metastatic at diagnosis and 20-50 % of patients with early BC who will eventually develop metastatic disease. Bone is the most frequent site of colonisation and the development of skeletal metastases depends on a complex multistep process, from dissemination and survival of malignant cells into circulation to the actual homing and metastases formation inside bone. Disseminated tumor cells (DTCs) can be detected in bone marrow in approximately 30 % of BC patients, likely reflecting the presence of minimal residual disease that would eventually account for subsequent metastatic disease. Patients with bone marrow DTCs have poorer overall survival compared with patients without them. Although bone-only metastatic disease seems to have a rather indolent behavior compared to visceral disease, bone metastases can cause severe and debilitating effects, including pain, spinal cord compression, hypercalcemia and pathologic fractures. Delivering an appropriate treatment is therefore paramount and ideally it should require interdisciplinary care. Multiple options are currently available, from bisphosphonates to new drugs targeting RANK ligand and radiotherapy. In this review we describe the mechanisms underlying bone colonization and provide an update on existing systemic and locoregional treatments for bone metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.